己酮可可碱注射液联合羟苯磺酸钙片治疗糖尿病周围神经病变患者的临床研究  

Clinical trial of pentoxifylline injection combined with calcium dobesilate tablets in treatment of patients with diabetic peripheral neuropathy

作　　者：郑海龙[1] 陈小盼[1] 那涵 韩倩菲 曹晓琳 ZHENG Hai-long;CHEN Xiao-pan;NA Han;HAN Qian-Fei;CAO Xiao-lin(Department of Endocrinology,The First Affiliated Hospital of Hainan Medical University,Haikou 570000,Hainan Province,China)

机构地区：[1]海南医学院第一附属医院内分泌内科,海南海口570000

出　　处：《中国临床药理学杂志》2023年第7期951-955,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：目的 观察己酮可可碱注射液联合羟苯磺酸钙片治疗糖尿病周围神经病变患者的临床效果及安全性。方法 将2型糖尿病(T2DM)合并糖尿病周围神经病变(DPN)患者按照给药方案分为对照组和试验组。对照组患者给予羟苯磺酸钙片500 mg,tid;试验组患者在对照组治疗的基础上,静脉滴注己酮可可碱注射液0.1 g,qd。比较2组临床总有效率、神经传导速度、糖尿病神经病变症状评分,以及内皮素1(ET-1)、一氧化氮(NO)、超氧化物歧化酶(SOD)和丙二醛(MDA)水平。结果 对照组和试验组各纳入74例。治疗后,试验组和对照组的总有效率分别为93.24%(69例/74例)和70.27%(52例/74例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的正中神经运动神经传导速度分别为(55.47±3.61)和(45.78±3.72)m·s^(-1),腓总神经运动神经传导速度分别为(51.66±3.42)和(44.34±3.69)m·s^(-1),正中神经感觉神经传导速度分别为(48.56±4.48)和(43.84±4.41)m·s^(-1),腓总神经感觉神经传导速度分别为(43.69±3.60)和(40.71±3.94)m·s^(-1),糖尿病神经病变症状评分中灼热感评分分别为(1.05±0.31)和(1.91±0.43)分,疼痛评分分别为(0.91±0.18)和(1.67±0.23)分,麻木评分分别为(1.40±0.39)和(1.94±0.31)分,感觉异常评分分别为(1.21±0.29)和(1.73±0.38)分,ET-1水平分别为(24.09±3.46)和(34.98±4.23)ng·L^(-1),NO水平分别为(3.93±0.82)和(3.28±0.71)μmol·L^(-1),SOD水平分别为(134.09±13.77)和(122.49±13.68)U·mL^(-1),MDA水平分别为(2.70±0.62)和(4.24±0.65)nmol·mL^(-1),差异均有统计学(均P<0.05)。试验组和对照组的药物不良反应主要有恶心呕吐、头痛、眩晕。试验组和对照组的药物不良反应发生率分别为6.76%(5例/74例)和9.46%(7例/74例),差异无统计学意义(P>0.05)。结论 己酮可可碱注射液联合羟苯磺酸钙片治疗糖尿病周围神经病变临床效果显著,并可加快神经传导速度,改善临床症状、内皮功能及氧化�Objective To observe the clinical effect and safety of pentoxobylline injection combined with calciumcalcium dobesilate tablets in the treatment of diabetic peripheral neuropathy.Methods Patients with type 2 diabetes mellitus(T2DM)complicated with diabetic peripheral neuropathy(DPN)were divided into control group and treatment group according to the treatment method.Control group was given calcium hydroxybenzene sulfonate tablets 500 mg,tid;treatment group was additionally given intravenous drip of pentoxifylline injection 0. 1 g,qd. The total clinical effective rate,nerve conduction velocity,diabetic neuropathy symptom score,endothelin- 1 ( ET - 1) ,nitric oxide ( NO) ,superoxide dismutase ( SOD) and malondialdehyde ( MDA) levels were comparedbetween the two groups. Results The control group and the treatment group were included in 74 cases. Aftertreatment,the clinical efficacies in the treatment and control groups were 93. 24% ( 69 cases /74 cases) and 70. 72%( 52 cases / 74 cases) ,respectively,and there was difference between two groups ( P < 0. 05) . After treatment,themedian nerve motor nerve conduction velocity of the treatment group and the control group were ( 55. 47 ± 3. 61) and( 45. 78 ±3. 72) m·s -1;the peroneal nerve motor nerve conduction velocity were ( 51. 66 ± 3. 42) and ( 44. 34 ± 3. 69)m·s -1;the median nerve sensory nerve conduction velocity were ( 48. 56 ± 4. 48) and ( 43. 84 ± 4. 41) m·s^(-1);theperoneal nerve sensory nerve conduction velocity were ( 43. 69 ± 3. 60) and ( 40. 71 ± 3. 94) m·s^(-1),respectively. Thesymptom score of diabetic neuropathy in the control and treatment groups: The scores of burning sensation were( 1. 05 ± 0. 31) and ( 1. 91 ± 0. 43) points;pain were ( 0. 91 ± 0. 18) and ( 1. 67 ± 0. 23) points;numbness were( 1. 40 ± 0. 39) and ( 1. 94 ± 0. 31) points;paresthesia were ( 1. 21 ± 0. 29) and ( 1. 73 ± 0. 38) points,respectively.The levels of ET - 1 were ( 24. 09 ± 3. 46 ) and ( 34. 98 ± 4. 23 ) ng · L^(-1);NO were ( 3. 93 ± 0. 82 ) and( 3. 28 ±

关 键 词：己酮可可碱注射液 羟苯磺酸钙片 糖尿病周围神经病变 

分 类 号：R97[医药卫生—药品]